BU
REGN icon

BBVA USA’s Regeneron Pharmaceuticals REGN Stock Holding History

BBVA USA’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$7.07M Sell
11,689
-211
-2% -$131K 0.41% 55
2021
Q2 		$6.65M Buy
+11,900
New +$6.03M 0.37% 61

Other funds holding REGN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

BBVA USA's REGN Position: Q3 2021 in Review

BBVA USA reduced its Regeneron Pharmaceuticals (REGN) stake by 1.8% in Q3 2021, selling an estimated $131K and leaving 11,689 shares worth $7.07M. The position accounts for 0.41% of the portfolio, ranked #55.

BBVA USA first reported a position in REGN in Q2 2021 and has held it in 2 quarters since. 1,017 funds tracked by Wall St. Rank hold REGN as of Q3 2021.

  • BBVA USA held 11,689 shares of Regeneron Pharmaceuticals worth $7.07M as of Q3 2021.
  • BBVA USA sold 211 Regeneron Pharmaceuticals shares in Q3 2021, an estimated $131K.
  • Regeneron Pharmaceuticals made up 0.41% of BBVA USA's portfolio in Q3 2021, its #55 holding.
  • BBVA USA first reported a position in Regeneron Pharmaceuticals in Q2 2021 and has held it in 2 quarters since.
  • 1,017 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2021.

Based on BBVA USA's 13F filing for Q3 2021, filed 4 Nov 2021.